K. Harlacker

Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC)

Jeffrey A. Sosman, K. T. Flaherty, Michael B. Atkins et al. · Journal of Clinical Oncology · 2008 · 83 citations

Medicine, Oncology, Pharmacology +16

A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts)

Jeffrey A. Sosman, Keith T. Flaherty, Michael B. Atkins et al. · Journal of Clinical Oncology · 2006 · 46 citations

Medicine, Oncology, Pharmacology +17

Effect of <i>BRAF^V600E</i> on response to sorafenib in advanced thyroid cancer patients

Marcia S. Brose, Andrea B. Troxel, Maryann Redlinger et al. · Journal of Clinical Oncology · 2009 · 32 citations

Medicine, Nuclear Medicine, Oncology +15

Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer

Christine Ciunci, Rodolfo F. Perini, Anjali Narayan Avadhani et al. · Cancer · 2013 · 24 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase II study of everolimus (E) and sorafenib (S) in patients (PTS) with metastatic differentiated thyroid cancer who have progressed on sorafenib alone.

Marcia S. Brose, Andrea B. Troxel, Mark Yarchoan et al. · Journal of Clinical Oncology · 2015 · 21 citations

Medicine, Pharmacology, Pharmacotherapy +15